UnThreaded | Threaded | Whole Thread (4) | Ignore Thread Prev Thread | Prev | Next | Next Thread
Author: dumaflotchie Big gold star, 5000 posts Old School Fool Add to my Favorite Fools Ignore this person (you won't see their posts anymore) Number: of 71869  
Subject: EXEL and Roche Date: 10/3/2012 8:11 PM
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Recommendations: 2
Reading this article and the stated talents and focus of Roche......one has to wonder if CABO might have found a potential partner in near future. I just don't see EXEL getting CABO to market by itself inclusive of all that is required outside of the science itself.

Sounds like Roche knows the business and can expedite the process.

Pure speculation of course but after reading this article, this sounds more encouraging to EXEL's opportunities......if it doesn't run out of money first.

http://seekingalpha.com/article/901801-exelixis-first-partne...

Fortunately for Exelixis, GDC-0973 represents Roche's main effort to protect its melanoma franchise. This guarantees an aggressive and efficient development program for the drug. Roche is 6 months behind GSK, but positive results should enable it to retain its presence in melanoma from 2015 onwards. In parallel, GDC-0973 is in several early stage combination trials.

Market ignores a major milestone - a buying opportunity

Exelixis now has a second drug in pivotal studies, in development by a strong and committed partner. Roche's commitment, a large commercial opportunity, favorable deal terms and a high likelihood of clinical success, make GDC-0973 an important asset for Exelixis that is still not reflected in the company's valuation. This creates a buying opportunity, as the market will eventually acknowledge the opportunity as well as the strategic importance of GDC-0973 to Roche.
Post New | Post Reply | Reply Later | Create Poll . Report this Post | Recommend it!
Print the post  
UnThreaded | Threaded | Whole Thread (4) | Ignore Thread Prev Thread | Prev | Next | Next Thread

Announcements

Post of the Day:
Berkshire Hathaway

Burger King's Play Not For Taxes?
What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and "#1 Media Company to Work For" (BusinessInsider 2011)! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement